(BNR) Burning Rock Biotech Limited BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BNR) Burning Rock Biotech Limited Complete Analysis Pack
See the Bigger Picture
This Burning Rock Biotech Limited BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
In-Hospital Business, China
Burning Rock Biotech Limited's In-Hospital Business in China is its main scale-up channel, because it fits the faster adoption of NGS-based oncology testing inside hospitals. As hospital penetration rises, this is the clearest Star candidate in the BCG matrix, with repeat testing helping build clinician stickiness and long-term test reuse. In China, the addressable hospital base is still large, so even modest penetration gains can lift volume fast.
OncoScreen IO, tissue pan-cancer
OncoScreen IO is Burning Rock Biotech Limited’s broad tissue pan-cancer assay, so it has clinical reach across many solid tumors and fits the fast-growing precision-oncology market. In hospital workflows, wider use can lift test volume and move it toward a dominant position. As one of Burning Rock Biotech Limited’s flagship tests, it is a key Star in the BCG matrix.
OncoCompass IO, liquid biopsy
OncoCompass IO fits Burning Rock Biotech Limited's Star bucket if usage keeps rising: liquid biopsy is less invasive than tissue sampling, and oncology adoption keeps widening. China had about 4.82 million new cancer cases in 2022, so precision-medicine testing has a huge base to tap. If this test keeps winning routine use, it can scale fast.
OncoCompass Target, NSCLC ctDNA
OncoCompass Target for NSCLC ctDNA sits in a star lane: China had about 1.06 million new lung cancer cases in 2022, and ctDNA fits the shift to minimally invasive monitoring. That gives Burning Rock Biotech Limited a large, high-growth pool if adoption keeps rising.
- Large NSCLC base in China
- ctDNA supports repeated monitoring
- High growth if adoption stays strong
Pharma Research and Development Services
Pharma Research and Development Services is the clearest Star-like engine in Burning Rock Biotech Limited’s BCG mix. It has 8 named partners, including AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA, which supports repeat external demand as oncology pipelines grow.
Clinical and biomarker work can scale with each new study, so revenue can rise even when project margins shift. The unit’s value is not just one contract; it is the ability to keep winning work across large drug makers and pipeline-heavy biotech clients.
- 8 major pharma and biotech partners
- Scales with oncology pipeline growth
- External demand stays active
- Margins vary by project
Burning Rock’s Oncology Stars Tap China’s Huge Cancer Market
Burning Rock Biotech Limited’s Stars are In-Hospital Business in China, OncoScreen IO, OncoCompass IO, OncoCompass Target for NSCLC ctDNA, and Pharma Research and Development Services. They sit in high-growth oncology niches with scale upside from China’s 4.82 million new cancer cases and 1.06 million lung cancer cases in 2022, plus 8 pharma partners.
| Star | Why it fits |
|---|---|
| In-Hospital Business | Large China hospital base |
| OncoScreen IO | Broad pan-cancer reach |
| Pharma R&D | 8 named partners |
What is included in the product
Detailed Word Document
Burning Rock Biotech’s BCG Matrix highlights which businesses to invest in, hold, or divest across all four quadrants.
Editable Excel File
One-page BCG matrix highlighting Burning Rock Biotech Limited’s portfolio pain points and priorities for quick executive review
Reference Sources
Burning Rock Biotech Limited’s reference sources provide a credible audit trail that supports faster, more confident decision-making.
Cash Cows
Central Laboratory Business
Burning Rock Biotech Limited’s Central Laboratory Business is one of its three operating segments and the most established service model, unlike newer hospital penetration efforts. Its mature workflows and repeat testing support steadier revenue and lower operating friction, which is why it fits the Cash Cow profile in the BCG Matrix. In 2025 filings, the segment remained the likeliest internal cash generator for the portfolio.
ColonCore, GI testing
Burning Rock Biotech Limited's ColonCore GI testing targets colorectal and broader gastrointestinal mutations plus MSI, so it sits in a mature diagnostic niche with recurring clinical use. That makes it a Cash Cow candidate if sample volume stays steady, because GI diagnostics are established rather than early-stage. Stable demand matters more here than fast growth.
OncoScreen ParpMatch
OncoScreen ParpMatch is an HRD-linked test, so it sits in a defined oncology pathway where repeat use is tied to treatment choice and follow-up. HRD is present in about 50% of ovarian cancers and 20% to 30% of breast cancers, which keeps demand steady but narrower than lung or broad pan-cancer testing. That profile fits a mature, cash-generating niche for Burning Rock Biotech Limited.
OncoCompass ParpMatch
OncoCompass ParpMatch is a niche PARP/HRD assay, so it fits a Cash Cow better than a Star in Burning Rock Biotech Limited’s BCG Matrix. Once treatment centers adopt a specialized test, switching costs and routine use can keep demand steady even if growth is slower than broad oncology panels. A stable, clinic-embedded workflow is the key cash engine here.
- Specialized PARP/HRD use case
- Lower growth, steadier demand
- Adoption can support repeat testing
- Cash Cow profile, not a Star
Established lung and GI NGS workflows
Burning Rock Biotech Limited’s lung and gastrointestinal NGS workflows fit Cash Cow status because they are already part of routine oncology care, especially in high-volume cancers where repeat testing supports treatment choice and monitoring. In its latest disclosed reporting cycle, the Company kept these core workflows as the main revenue base, with lower go-to-market spend than newer assays.
- High-volume lung and GI testing
- Embedded in oncology decision-making
- Recurring service revenue profile
- Lower promo spend than growth tests
That mix usually means steadier gross profit and less sales friction, which is classic Cash Cow behavior.
Burning Rock’s Steady Oncology Cash Cows
Burning Rock Biotech Limited’s Cash Cow set is its mature, repeat-use oncology tests: Central Laboratory Business, GI panels, and PARP/HRD assays. These niches have steadier demand than newer assays; HRD is seen in about 50% of ovarian cancers and 20% to 30% of breast cancers, supporting recurring clinical use.
| Item | Data |
|---|---|
| HRD in ovarian cancer | About 50% |
| HRD in breast cancer | 20% to 30% |
What You See Is What You Get
Burning Rock Biotech Limited Reference Sources
The Burning Rock Biotech Limited BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages, no hidden changes—just the full, ready-to-use report. Once purchased, the complete file is instantly available for download and use. What you preview is exactly what you get.
Dogs
Lymphoma testing portfolio
Burning Rock Biotech Limited's lymphoma testing portfolio is narrower than its lung or GI testing lines, so the addressable clinical volume is smaller and growth can lag. That usually means weaker scale economics and less pricing power, which fits a Dog profile in BCG terms. Lymphoma is more of a niche support test than a core 2025/2026 growth engine.
Thyroid testing portfolio
Thyroid testing sits inside Burning Rock Biotech Limited’s broader coverage list, but it is likely a low-volume service versus the flagship lung, pan-cancer, and MRD lines. With limited scale and weaker contribution to testing mix, it fits the Dog quadrant in a BCG Matrix. In BCG terms, a Dog is a low-share, low-growth business that ties up resources without clear growth upside.
Ovarian testing portfolio
Ovarian testing sits in Burning Rock Biotech Limited’s coverage, but it is a niche pool versus lung cancer. Ovarian cancer had about 324,000 new cases and 207,000 deaths worldwide in 2022, yet screening demand stays limited, so test volume and revenue share are likely small. That profile fits Dog status: low share, modest growth, and little chance to anchor the portfolio.
Pancreatic testing portfolio
Burning Rock Biotech Limited's pancreatic testing portfolio fits the Dog box because pancreatic cancer is a small, hard-to-screen market: it is about 3% of new cancer cases in the United States, but it drives about 8% of cancer deaths. That mix supports clinical need, yet routine test volume stays well below lung, breast, and colorectal panels, so growth and share are limited.
- Small addressable market
- Low repeat testing volume
- Weak scale economics
- Hard to justify heavy capex
For Burning Rock Biotech Limited, that means the portfolio can stay clinically useful, but it is unlikely to be a major profit pool unless adoption jumps sharply or reimbursement widens.
Bladder testing portfolio
Bladder testing fits Burning Rock Biotech Limited’s cancer coverage set, but it sits in a narrower market than flagship oncology panels. Bladder cancer remains a valid diagnostic area, yet its smaller addressable pool and lower revenue scale usually limit growth and share gains, which is why this portfolio is most consistent with a Dog in the BCG Matrix.
- Valid diagnostic line, but niche demand.
- Smaller market caps growth potential.
- Lower scale weakens BCG rank.
- Best fit: Dog.
Burning Rock’s Niche Cancer Tests Look Like Dogs, Not Growth Drivers
Burning Rock Biotech Limited’s lymphoma, thyroid, ovarian, pancreatic, and bladder tests look like Dogs: niche demand, low volume, and weak scale. Ovarian cancer had 324,000 new cases and 207,000 deaths worldwide in 2022, while pancreatic cancer is about 3% of U.S. new cases but 8% of deaths. These lines can stay useful, but they are not core growth engines.
| Test | Dog signal | Key data |
|---|---|---|
| Ovarian | Niche | 324k cases, 207k deaths |
| Pancreatic | Low scale | 3% cases, 8% deaths |
Question Marks
Myriad myChoice tumor testing, China
Burning Rock Biotech Limited has a development and commercialization license for Myriad myChoice tumor testing in China, which gives it a real entry point in HRD testing. HRD use can expand as precision oncology grows and PARP-linked treatment selection rises, but China share is still early-stage, so the product remains a Question Mark. The upside is clear, but the win rate still depends on adoption, reimbursement, and clinical proof.
DetermaRx, China
Burning Rock Biotech Limited licensed DetermaRx from Oncocyte for China, and the test fits a large need: GLOBOCAN 2022 estimates about 1.06 million new lung cancer cases in China. It targets early-stage lung cancer risk stratification, so the use case is clinically relevant and adoption can build if hospitals see clear utility. But its share base is still not proven, which keeps DetermaRx in Question Mark territory.
HRD companion diagnostics, China
HRD companion diagnostics in China are tied to PARP inhibitor selection, and demand is still rising as more ovarian and breast cancer patients are tested. The NMPA has already cleared 3 PARP inhibitors, but HRD testing standards and payer coverage are still uneven. Burning Rock Biotech Limited has a product set here, yet it has not built clear market leadership across China. That makes this a Question Mark: growth is real, but share is still being won.
Early-stage NSCLC risk stratification
Early-stage NSCLC risk stratification around DetermaRx sits in Burning Rock Biotech Limited's Question Mark bucket: NSCLC is about 85% of lung cancers, so the care-pathway pool is large, but the test's share is still hard to pin down.
If adoption rises in post-surgery decision making, the addressable market can widen fast, but current penetration and reimbursement traction remain uncertain.
- Large unmet need in early NSCLC
- Market can expand with adoption
- Current share is still unclear
Partner-led new assay pipeline
Burning Rock Biotech Limited has 8 partner-led assay tracks with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA, which can seed new diagnostics. These programs sit in a growing precision-oncology market, but each still needs clinical uptake, reimbursement, and scale, so revenue is not yet proven. That mix of high upside and low market share makes them Question Marks in the BCG Matrix.
- 8 partner programs
- High growth, low proof
- Adoption still the key hurdle
High-upside oncology bets, but adoption is still the hurdle
Burning Rock Biotech Limited's Question Marks are still early-share bets: Myriad myChoice, DetermaRx, and other partner assays target large China oncology pools, but adoption, reimbursement, and clinical proof are not yet secure. That keeps upside high and market share low, so growth is real but not yet converted into durable revenue.
| Item | Signal |
|---|---|
| Myriad myChoice | HRD growth |
| DetermaRx | NSCLC demand |
| 8 partner assays | Pipeline upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.